High-density lipoprotein cholesterol in the cardiovascular equation: Does the "good" still count?

Atherosclerosis

Volumn 180, Issue 2, 2005, Pages 217-223

  Alsheikh Ali, Alawi A ^a   Kuvin, Jeffrey T ^a   Karas, Richard H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; High density lipoprotein; Lipoproteins; Statins

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; GENE MUTATION; GENETIC DISORDER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MORTALITY; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS; EPIDEMIOLOGIC STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RISK FACTORS;

EID: 23044493915     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.01.003     Document Type: Review

References (72)

1. D. Steinberg, and A.M. Gotto Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside JAMA 282 1999 2043 2050
2. J.C. LaRosa, D. Hunninghake, and D. Bush The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association Circulation 81 1990 1721 1733
3. Hugher S, OTC simvastatin 10 mg gets go ahead in UK, www.theheart.org ; accessed 5/12/2004.
4. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVET IT-TIMI 22 Study) N Engl J Med 350 2004 1495 1504
5. E.J. Topol Intensive statin therapy - a sea change in cardiovascular prevention N Engl J Med 350 2004 1562 1564
6. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. G. Kolata Scientists Begin to Question Benefit of "Good" Cholesterol 3/15/2004 The New York Times
8. Hughes S., Doctors confused over HDL, www.theheart.org ; accessed 3/15/2004.
9. D.J. Gordon, and B.M. Rifkind High-density lipoprotein - the clinical implications of recent studies N Engl J Med 321 1989 1311 1316
10. G. Franceschini Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease Am J Cardiol 88 2001 9N 13N
11. D.P. Barr, E.M. Russ, and H.A. Eder Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions Am J Med 11 1951 480 493
12. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
13. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
14. P.W. Wilson, R.J. Garrison, W.P. Castelli, M. Feinleib, P.M. McNamara, and W.B. Kannel Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols Am J Cardiol 46 1980 649 654
15. W.P. Castelli, R.J. Garrison, P.W. Wilson, R.D. Abbott, S. Kalousdian, and W.B. Kannel Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 1986 2835 2838
16. Coronary Drug Project Research Group Coronary Drug Project: clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
17. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
18. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
19. S.J. Robins, D. Collins, and J.T. Wittes Relation of gemfibrozil treatment and lipid levels with major coronary events, VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
20. P.K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I Circulation 104 2001 2376 2383
21. M.I. Mackness, S. Arrol, C. Abbott, and P.N. Durrington Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
22. J.T. Kuvin, and R.H. Karas The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers Curr Opin Cardiol 18 2003 295 300
23. J.T. Kuvin, A.R. Patel, and M. Sidhu Relation between high-density lipoprotein cholesterol and peripheral vasomotor function Am J Cardiol 92 2003 275 279
24. I.S. Yuhanna, Y. Zhu, and B.E. Cox High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase Nat Med 7 2001 853 857
25. M.E. Ramet, M. Ramet, and Q. Lu High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life J Am Coll Cardiol 41 2003 2288 2297
26. J.J. Badimon, L. Badimon, and V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1990 1234 1241
27. A. Miyazaki, S. Sakuma, and W. Morikawa Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits Arterioscler Thromb Vasc Biol 15 1995 1882 1888
28. S. Ameli, A. Hultgardh-Nilsson, and B. Cercek Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1994 1935 1941
29. B. De Geest, Z. Zhao, D. Collen, and P. Holvoet Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice Circulation 96 1997 4349 4356
30. C. Paszty, N. Maeda, J. Verstuyft, and E.M. Rubin Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice J Clin Invest 94 1994 899 903
31. A.S. Plump, C.J. Scott, and J.L. Breslow Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse Proc Natl Acad Sci USA 91 1994 9607 9611
32. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
33. S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs, and M. Krieger Identification of scavenger receptor SR-BI as a high density lipoprotein receptor Science 271 1996 518 520
34. B.L. Trigatti, M. Krieger, and A. Rigotti Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis Arterioscler Thromb Vasc Biol 23 2003 1732 1738
35. B. Trigatti, H. Rayburn, and M. Vinals Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology Proc Natl Acad Sci USA 96 1999 9322 9327
36. A. Rigotti, B.L. Trigatti, M. Penman, H. Rayburn, J. Herz, and M. Krieger A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism Proc Natl Acad Sci USA 94 1997 12610 12615
37. M.L. Varban, F. Rinninger, and N. Wang Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol Proc Natl Acad Sci USA 95 1998 4619 4624
38. K.F. Kozarsky, M.H. Donahee, J.M. Glick, M. Krieger, and D.J. Rader Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse Arterioscler Thromb Vasc Biol 20 2000 721 727
39. B. Agerholm-Larsen, B.G. Nordestgaard, R. Steffensen, G. Jensen, and A. Tybjaerg-Hansen Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene Circulation 101 2000 907 912
40. S. Zhong, D.S. Sharp, and J.S. Grove Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 1996 2917 2923
41. Y. Moriyama, T. Okamura, and A. Inazu A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency Prev Med 27 1998 659 667
42. J.M. Ordovas, L.A. Cupples, and D. Corella Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study Arterioscler Thromb Vasc Biol 20 2000 1323 1329
43. M.E. Brousseau, J.J. O'Connor Jr., and J.M. Ordovas Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial Arterioscler Thromb Vasc Biol 22 2002 1148 1154
44. C. Serfaty-Lacrosniere, F. Civeira, and A. Lanzberg Homozygous Tangier disease and cardiovascular disease Atherosclerosis 107 1994 85 98
45. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
46. J. Shepherd, S.M. Cobbe, I. Ford for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
47. F.M. Sacks, M.A. Pfeffer, L.A. Moye for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
48. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
49. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
50. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
51. F.M. Sacks, A.M. Tonkin, and J. Shepherd Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
52. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, and J. Kjekshus Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
53. J. Shepherd, G.J. Blauw, and M.B. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
54. C.M. Ballantyne, J.A. Herd, and L.L. Ferlic Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy Circulation 99 1999 736 743
55. T.R. Pedersen, A.G. Olsson, and O. Faergeman Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) Circulation 97 1998 1453 1460
56. J.T. Kuvin, A.R. Patel, K.A. Sliney, N.G. Pandian, and R.H. Karas Do ultra-low levels of low-density lipoprotein cholesterol confer additional benefit to the endothelium? Am J Cardiol 95 2005 93 95
57. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
58. P.W. Wilson, K.M. Anderson, and W.P. Castelli Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study Am J Med 90 1991 11 16
59. J.T. Kuvin, M.E. Ramet, A.R. Patel, N.G. Pandian, M.E. Mendelsohn, and R.H. Karas A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression Am Heart J 144 2002 165 172
60. M. Navab, G.M. Anantharamaiah, and S. Hama Oral administration of an Apo A-I mimetic peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol Circulation 105 2002 290 292
61. J. Ou, Z. Ou, and D.W. Jones L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease Circulation 107 2003 2337 2341
62. Z. Ou, J. Ou, A.W. Ackerman, K.T. Oldham, and K.A. Pritchard Jr. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells Circulation 107 2003 1520 1524
63. M. Sugano, and N. Makino Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits J Biol Chem 271 1996 19080 19083
64. M. Sugano, N. Makino, and S. Sawada Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits J Biol Chem 273 1998 5033 5036
65. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
66. C.W. Rittershaus, D.P. Miller, and L.J. Thomas Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis Arterioscler Thromb Vasc Biol 20 2000 2106 2112
67. H.V. Kothari, K.J. Poirier, W.H. Lee, and Y. Satoh Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters Atherosclerosis 128 1997 59 66
68. B.J. Gaynor, T. Sand, R.W. Clark, R.J. Aiello, M.J. Bamberger, and J.B. Moberly Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition Atherosclerosis 110 1994 101 109
69. G.J. de Grooth, J.A. Kuivenhoven, and A.F. Stalenhoef Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study Circulation 105 2002 2159 2165
70. M.E. Brousseau, E.J. Schaefer, and M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
71. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
72. L. Mosca, L.J. Appel, and E.J. Benjamin Evidence-based guidelines for cardiovascular disease prevention in women Circulation 109 2004 672 693